TABLE 1.

Treatment of Control and PCK Rats with Gefitinib

		Control	Control	PCK	PCK	PCK
	Gefitinib (mg/kg)	0	10	0	2	10
Body weight (g)		344 ± 16	334 ± 16	321 ± 7	308 ± 11	310 ± 5
Liver/body weight (%)		4.1 ± 0.3	3.7 ± 0.4	4.1 ± 0.1	4.5 ± 0.7	4.3 ± 0.1
Kidney/body weight (%)		0.35 ± 0.01	0.33 ± 0.02	0.99 ± 0.10**	1.0 ± 0.20	1.0 ± 0.12
Liver cyst index (%)		ND	ND	7.9 ± 2.7	6.7 ± 1.6	4.1 ± 1.3*
Kidney cyst index (%)		ND	ND	23 ± 2	23 ± 7	27 ± 7
Ki-67-labeling index (%) (bile duct)		0.51 ± 0.22	0.39 ± 0.21	7.9 ± 2.3**	5.8 ± 3.1	3.5 ± 2.1*
TUNEL-labeling index (%) (bile duct)		0.17 ± 0.05	0.18 ± 0.10	1.2 ± 0.4**	1.6 ± 0.5	2.2 ± 0.4*
TUNEL-labeling index (%) (hepatocyte)		0.23 ± 0.10	0.22 ± 0.48	0.38 ± 0.15	0.29 ± 0.09	0.36 ± 0.20
Aspertate aminotransferase (IU/L)		134 ± 9	149 ± 19	159 ± 37	158 ± 24	139 ± 11
Alanine aminotransferase (IU/L)		45 ± 2	41 ± 5	65 ± 5	63 ± 3	66 ± 4
Alkaline phosphatase (U/L)		1141 ± 199	994 ± 231	992 ± 146	921 ± 242	1067 ± 62
Total protein (g/dL)		6.2 ± 0.2	6.3 ± 0.2	6.5 ± 0.1	6.5 ± 0.2	6.4 ± 0.2
Albumin (g/dL)		3.1 ± 0.1	3.1 ± 0.2	2.9 ± 0.1	2.8 ± 0.1	2.9 ± 0.1
Blood urea nitrogen (mg/dL)		17 ± 1	19 ± 2	18 ± 1	20 ± 1	19 ± 1
Creatinine (mg/dL)		0.22 ± 0.02	0.19 ± 0.01	0.20 ± 0.02	0.23 ± 0.02	0.22 ± 0.02

ND, not determined. n = 5. 

^*P < 0.05; PCK-treated versus PCK-untreated. 

^**P < 0.01; PCK-untreated versus control untreated.